MedTrace Logo

Beta-glucan on Fecal Microflora in Polypectomized Patients

NCT00893659 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 69

Last updated 2015-07-24

No results posted yet for this study

Summary

The aim of this study is to determine the effect of the potential prebiotic beta-glucan on the intestinal microflora, the bacterial enzyme activity (beta-glucuronidase and beta-glucosidase) in the feces, the fecal pH and the concentration of fecal short-chain fatty acid in polypectomized patients. Also the in vitro anti-cyto- and anti-genotoxicity of fecal water will be examined on human cell culture (HT29). During the trial, patient's clinical symptoms (intestinal habits), physical activity, well-being and food intake will be recorded.

Conditions

  • Polypectomized Patients

Interventions

DIETARY_SUPPLEMENT

wheat bread with beta-glucan

3 g beta-glucan in approximately 200 g of wheat bread per day for 3 months

DIETARY_SUPPLEMENT

wheat bread without beta-glucan

Approximately 200 g of wheat bread (without beta-glucan supplementation) per day for 3 months

Sponsors & Collaborators

  • JOTIS S.A. FOOD INDUSTRY, GREECE

    collaborator UNKNOWN

  • Harokopio University

    lead OTHER

Principal Investigators

  • Adamantini Kyriacou, Ass. Professor · Harokopio University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-01-31
Primary Completion
2012-12-31
Completion
2015-07-31

Countries

  • Greece

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00893659 on ClinicalTrials.gov